Keywords: Ablynx, Spirogen, Research, Cytotoxic drugs, Nanobodies, Solent Pharma, Idecortex, Idebnone, Cognitive disorders

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

Article | 25 February 2013

Belgium drug developer  Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with closely-held UK-based Spirogen to evaluate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Spirogen

Ablynx

Solent Pharma

Go to company listing

Related Drugs

Idecortex

idebenone

Go to drug listing